Efficacy of treatment with combination dapagliflozin & metformin versus metformin alone in improving insulin resistance and hyperandrogenemia in overweight and obese women with polycystic ovary syndrome.

Dr Vishal Agarwal0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年6月26日

试验速览

暂无简介。

•1)Body mass index (BMI) more than or equal to 23 kg/m2 2)PCOS diagnosis by Rotterdam 2003 criteria 3)No pregnancy plans within next 6 months

•1)Women who are pregnant or plan to become pregnant 2)Serious liver dysfunction or chronic kidney disease (AST or ALT > 3 times the upper limit of normal, or eGFR <30 ml/min/1.73 m2) 3)Congenital adrenal hyperplasia such as 21-hydroxylase deficiency, hyperprolactinemia, Cushing syndrome, androgen-producing tumors of the adrenal gland or ovary 4)Other endocrine diseases include poorly controlled thyroid diseases (hyperthyroidism or hypothyroidism), acromegaly, type 2 diabetes 5)Patients taking any medication that would affect insulin resistance or hyperandrogenemia (i.e. Thiazolidinediones, Glucagon like peptide-1 Receptor agonists, Metformin) in the past six weeks 6)Patients taking letrozole, clomiphene, oral contraceptive, glucocorticoid, gonadotropin, gonadotropin releasing hormone agonist, anti-androgen drug (spironolactone, cycloproterenone acetate, Flutamide etc.) and/or other drugs for PCOS in the past three months 7)History of recurrent urinary tract infection 8)Currently participating in weight loss programs or weight change in the past 3 months ( > 5% current body weight) or have a history of gastrointestinal surgery.

发起方

Dr Vishal Agarwal